CL2023000194A1 - Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo - Google Patents

Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo

Info

Publication number
CL2023000194A1
CL2023000194A1 CL2023000194A CL2023000194A CL2023000194A1 CL 2023000194 A1 CL2023000194 A1 CL 2023000194A1 CL 2023000194 A CL2023000194 A CL 2023000194A CL 2023000194 A CL2023000194 A CL 2023000194A CL 2023000194 A1 CL2023000194 A1 CL 2023000194A1
Authority
CL
Chile
Prior art keywords
compound
oxadiazol
formulation
methyl
low dose
Prior art date
Application number
CL2023000194A
Other languages
English (en)
Spanish (es)
Inventor
Dustin James Mergott
William Brian Kielbasa
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2023000194A1 publication Critical patent/CL2023000194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CL2023000194A 2020-07-23 2023-01-19 Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo CL2023000194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063055362P 2020-07-23 2020-07-23

Publications (1)

Publication Number Publication Date
CL2023000194A1 true CL2023000194A1 (es) 2023-07-21

Family

ID=77338898

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000194A CL2023000194A1 (es) 2020-07-23 2023-01-19 Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo

Country Status (21)

Country Link
US (1) US20230338349A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185291B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535034A (cg-RX-API-DMAC7.html)
KR (1) KR20230043905A (cg-RX-API-DMAC7.html)
CN (1) CN116323604A (cg-RX-API-DMAC7.html)
AR (1) AR123031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021312894B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000975A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186808A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000194A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000594A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000009A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005057A (cg-RX-API-DMAC7.html)
ES (1) ES3039536T3 (cg-RX-API-DMAC7.html)
IL (1) IL300023A (cg-RX-API-DMAC7.html)
JO (1) JOP20230018A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000993A (cg-RX-API-DMAC7.html)
PE (1) PE20231031A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550177A1 (cg-RX-API-DMAC7.html)
TW (1) TW202220650A (cg-RX-API-DMAC7.html)
WO (1) WO2022020663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735190B (zh) * 2016-07-22 2019-11-26 深圳市大富科技股份有限公司 Usb金属管件加工设备及其上模板
TWI654978B (zh) * 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy

Also Published As

Publication number Publication date
EP4185291C0 (en) 2025-07-09
CA3186808A1 (en) 2022-01-27
AU2021312894B2 (en) 2025-09-11
PE20231031A1 (es) 2023-07-10
IL300023A (en) 2023-03-01
BR112023000975A2 (pt) 2023-02-07
KR20230043905A (ko) 2023-03-31
CN116323604A (zh) 2023-06-23
ES3039536T3 (en) 2025-10-22
ECSP23005057A (es) 2023-02-28
AR123031A1 (es) 2022-10-26
MX2023000993A (es) 2023-03-01
PH12023550177A1 (en) 2024-03-18
AU2021312894A1 (en) 2023-02-23
EP4185291A1 (en) 2023-05-31
US20230338349A1 (en) 2023-10-26
JOP20230018A1 (ar) 2023-01-23
DOP2023000009A (es) 2023-02-15
CO2023000594A2 (es) 2023-01-26
WO2022020663A1 (en) 2022-01-27
EP4185291B1 (en) 2025-07-09
JP2023535034A (ja) 2023-08-15
TW202220650A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
MX2023005462A (es) Compuestos macrociclicos y metodos para usarlos.
MX2022005503A (es) Composiciones farmaceuticas de apixaban de desintegracion oral.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
PE20241327A1 (es) Tratamiento de trastornos hepaticos con un agonista del thr-beta
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CO2023000594A2 (es) Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4- oxadiazol-3-ilo
AR129937A1 (es) Derivados de 1,3,4-oxadiazol como inhibidores selectivos de histona desacetilasa 6
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
CO2026000726A2 (es) Una forma farmacéutica sólida de dosificación bucodispersable de safinamida
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2025010159A2 (es) Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo
PE20252741A1 (es) Formulaciones de dosis de una sola unidad de alta concentracion y metodos de uso de estas
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
DOP2024000018A (es) Antagonistas del receptor muscarínico 4 y métodos de uso
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
UY39649A (es) Compuesto para el tratamiento de trastornos cognitivos